Key facts
- P 3 Therapeutics’s last known valuation is $5.4M (Apr 2025).
- It has raised $110K.
- Notable investors include Vesna Deep Tech Fund, SEE UP Accelerator.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for P 3 Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for P 3 Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About P 3 Therapeutics
Developer of novel anti-inflammatory drugs designed to address unmet needs in treating Spondyloarthritis. The company's proprietary technology activates three anti-inflammatory targets while leveraging AI-driven "scaffold hopping" and generative AI for lead optimization, enabling medical professionals to provide treatment for chronic immune-mediated inflammatory disorders.
- Sector
- Healthcare
- HQ
- Zagreb, Croatia
- Founded
- 2024
- Employees
- 2
- Website
- p3therapeutics.eu/
- Ownership
- Privately Held (backing)
P 3 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in P 3 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on P 3 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.